Accession Number : ADA488589

Title :   Identification of Tumor Rejection Antigens for Breast Cancer Using a Mouse Tumor Rejection Model

Descriptive Note : Annual rept. 28 Apr 2007-27 Apr 2008


Personal Author(s) : Disis, Mary L

Full Text :

Report Date : May 2008

Pagination or Media Count : 9

Abstract : Our goal in this proposal is to identify antigens that are associated with tumor rejection. Whereas this study would not be possible in humans, we have recently established a tumor rejection model by implanting the mouse tumors derived from neu-tg mice into the parental FVB/N mouse, who are identical in every way except were NOT engineered to develop breast cancer. In our model, none of the parental FVB/N mice develop tumor while all of the neu-tg mice that received tumor implantation succumb to their disease despite having endogenous immunity to some proteins expressed by the tumor. Interestingly, the tumor rejection that occurs is not solely mediated by immunity to neu, the major cause of the cancer (similar to human HER-2/neu). We proposed to use subtractive SEREX, a method established in the laboratory to screen for antigens that are specifically induced by tumor rejection. The tumor antigens that have immunogenic human homologues will be further studied by using them to vaccinate the neu-tg mice to see if such a vaccine will prevent the cancers. The human homologues of these proteins, identified as described in this proposal, will be the basis for a multi-antigen vaccine to prevent breast cancer relapse in pre-menopausal patients with ER negative breast cancer.


Subject Categories : Medicine and Medical Research

Distribution Statement : APPROVED FOR PUBLIC RELEASE